Valtoco FDA Approval History
FDA Approved: Yes (First approved January 10, 2020)
Brand name: Valtoco
Generic name: diazepam
Dosage form: Nasal Spray
Company: Neurelis, Inc.
Treatment for: Epilepsy
Valtoco (diazepam) is a benzodiazepine nasal spray for the short-term treatment of epilepsy cluster seizures.
- Valtoco is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
- Valtoco is a ready-to-use, single-dose nasal spray device. A dose is administered as a single spray intranasally into one nostril. Higher doses may require two nasal spray devices, with once spray administered into each nostril. A second dose, when required, may be administered at least 4 hours after the initial dose. No more than 2 doses should be administered to treat a single episode.
- Diazepam is a Schedule IV controlled substance and can produce drug dependence. It is recommended that Valtoco be used to treat no more than one episode every five days and no more than five episodes per month.
- The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.
Development Timeline for Valtoco
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.